DelveInsight’s “Osteomyelitis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Osteomyelitis, historical and forecasted epidemiology as well as the Osteomyelitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
Some of the key facts of the Osteomyelitis Market Report:
-
The Osteomyelitis market size is anticipated to grow with a significant CAGR during the study period (2019-2032).
-
Key Osteomyelitis Companies: Durata Therapeutics Inc, Allergan plc, Basilea Pharmaceutica, Adaptive Phage Therapeutics, and others
-
Key Osteomyelitis Therapies: DALVANCE (dalbavancin), Lefamulin, CF 296, Bacteriophage therapy, and others
-
The diagnosed incidence cases of osteomyelitis in 7MM countries were ~162,000 in 2021.
-
In May 2020, AbbVie announced that it had completed its acquisition of Allergan plc in a deal worth about USD 63 billion, following receipt of regulatory approval from all government authorities required by the transaction agreement and the Irish High Court.
-
The Osteomyelitis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Osteomyelitis pipeline products will significantly revolutionize the Osteomyelitis market dynamics.
Osteomyelitis Overview
Osteomyelitis represents a severe bone infection that can manifest as either an acute or chronic condition. This inflammatory ailment involves the bone and its structures and is typically triggered by pyogenic organisms that disseminate through the bloodstream, fractures, or surgical procedures. Normally, healthy and intact bone demonstrates resistance to infection.
However, susceptibility to disease arises when a significant amount of bacteria is introduced, often due to trauma, restricted blood flow (ischemia), or the presence of foreign objects which expose binding sites for microorganisms. Infection can occur via several routes: hematogenous spread through the bloodstream from a distant source, contiguous dissemination from nearby tissues and joints, or direct introduction from trauma or surgery. Hematogenous osteomyelitis is more common in children, usually affecting long bones, while in adults, it often targets the vertebrae. Contiguous osteomyelitis is typically associated with trauma and related surgeries in younger adults, whereas in older adults, infections are commonly linked to pressure ulcers and infected joint replacements.
Osteomyelitis related to vascular issues is prevalent among individuals with diabetes, particularly due to compromised blood flow in the lower limbs, leading to impaired local immunity and delayed wound healing, which facilitates the spread of infection. Hematogenous osteomyelitis tends to be caused by a single microbial agent, whereas infections stemming from contiguous spread or direct inoculation are usually caused by multiple or single microbes. The specific pathogens involved often vary depending on the patient’s age.
Treating osteomyelitis effectively requires a multidisciplinary approach involving various medical and surgical specialties. Key components of therapy include surgically containing the infection and administering prolonged courses of antibiotics. Antibiotic treatment plays a central role and should be continued for an extended period. While laboratory tests can aid in diagnosis, they typically lack specificity for osteomyelitis. Variables such as leukocyte count, elevated erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) levels may or may not be present. Monitoring CRP levels can be particularly useful in assessing the response to treatment. Blood cultures may yield positive results, especially in cases of hematogenous osteomyelitis affecting specific bones. Radiographic imaging is crucial for evaluating suspected cases of osteomyelitis. Additionally, obtaining a bone biopsy, either through open surgery or percutaneous means, is essential for confirming the diagnosis, identifying the causative pathogen, and determining its susceptibility to guide antibiotic therapy.
Get a Free sample for the Osteomyelitis Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/sample-request/osteomyelitis-market
Osteomyelitis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Osteomyelitis Epidemiology Segmentation:
The Osteomyelitis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
-
Total Prevalence of Osteomyelitis
-
Prevalent Cases of Osteomyelitis by severity
-
Gender-specific Prevalence of Osteomyelitis
-
Diagnosed Cases of Episodic and Chronic Osteomyelitis
Download the report to understand which factors are driving Osteomyelitis epidemiology trends @ Osteomyelitis Epidemiology Forecast
Osteomyelitis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Osteomyelitis market or expected to get launched during the study period. The analysis covers Osteomyelitis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Osteomyelitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Osteomyelitis Therapies
-
DALVANCE (dalbavancin)
-
Lefamulin
-
CF 296
-
Bacteriophage therapy
Osteomyelitis Key Companies
-
Durata Therapeutics Inc
-
Allergan plc
-
Basilea Pharmaceutica
-
Adaptive Phage Therapeutics
Discover more about therapies set to grab major Osteomyelitis market share @ Osteomyelitis Treatment Landscape
Osteomyelitis Treatment Market
Optimal treatment of skeletal infections requires collaborative efforts of pediatricians, orthopedic surgeons, and interventional radiologists. Antibiotics can make up an effective treatment regimen but may include the surgical removal of dead bone in chronic osteomyelitis. Painkillers are given to ease the pain. In neglected cases with flexion contractures, prolonged physical therapy is required.
A few major unmet needs in the market include lack of novel and effective strategies for antibiotic therapy, challenges in diagnosis, difficulty in establishing microbial etiology, antimicrobial resistance, and lack of clarity in the role of surgical debridement in treating chronic osteomyelitis.
Osteomyelitis Market Opportunities
There are ongoing trials addressing unanswered questions, such as (CAR) T-cell therapy
Scope of the Osteomyelitis Market Report:
-
Study Period: 2019–2032
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Osteomyelitis Companies: Durata Therapeutics Inc, Allergan plc, Basilea Pharmaceutica, Adaptive Phage Therapeutics, and others
-
Key Osteomyelitis Therapies: DALVANCE (dalbavancin), Lefamulin, CF 296, Bacteriophage therapy, and others
-
Osteomyelitis Therapeutic Assessment: Osteomyelitis current marketed and Osteomyelitis emerging therapies
-
Osteomyelitis Market Dynamics: Osteomyelitis market drivers and Osteomyelitis market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Osteomyelitis Unmet Needs, KOL’s views, Analyst’s views, Osteomyelitis Market Access and Reimbursement
To know more about Osteomyelitis companies working in the treatment market, visit @ Osteomyelitis Clinical Trials and Therapeutic Assessment
Table of Contents
1. Osteomyelitis Market Report Introduction
2. Executive Summary for Osteomyelitis
3. SWOT analysis of Osteomyelitis
4. Osteomyelitis Patient Share (%) Overview at a Glance
5. Osteomyelitis Market Overview at a Glance
6. Osteomyelitis Disease Background and Overview
7. Osteomyelitis Epidemiology and Patient Population
8. Country-Specific Patient Population of Osteomyelitis
9. Osteomyelitis Current Treatment and Medical Practices
10. Osteomyelitis Unmet Needs
11. Osteomyelitis Emerging Therapies
12. Osteomyelitis Market Outlook
13. Country-Wise Osteomyelitis Market Analysis (2019–2032)
14. Osteomyelitis Market Access and Reimbursement of Therapies
15. Osteomyelitis Market Drivers
16. Osteomyelitis Market Barriers
17. Osteomyelitis Appendix
18. Osteomyelitis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Osteomyelitis Pipeline
“Osteomyelitis Pipeline Insight, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Osteomyelitis market. A detailed picture of the Osteomyelitis pipeline landscape is provided, which includes the disease overview and Osteomyelitis treatment guidelines.
Osteomyelitis Epidemiology
DelveInsight’s ‘Osteomyelitis Epidemiology Forecast to 2032’ report delivers an in-depth understanding of the disease, historical and forecasted Osteomyelitis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/